Article (Scientific journals)
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem, Guy; Beguin, Yves; Fassotte, Marie-France et al.
1999In Blood, 94 (2), p. 429-33
Peer Reviewed verified by ORBi
 

Files


Full Text
118.pdf
Publisher postprint (302.24 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Combined Modality Therapy; Diagnosis, Differential; Disease-Free Survival; Female; Fibrosis; Fluorine Radioisotopes/diagnostic use/pharmacokinetics; Fluorodeoxyglucose F18/diagnostic use/pharmacokinetics; Hodgkin Disease/drug therapy/mortality/pathology/radionuclide imaging/radiotherapy; Humans; Life Tables; Lymphoma, Non-Hodgkin/drug therapy/mortality/pathology/radionuclide imaging/radiotherapy; Male; Middle Aged; Neoplasm, Residual; Predictive Value of Tests; Prognosis; Survival Analysis; Tissue Distribution; Tomography, Emission-Computed/methods; Tomography, X-Ray Computed
Abstract :
[en] A residual mass after treatment of lymphoma is a clinical challenge, because it may represent vital tumor as well as tissue fibrosis. Metabolic imaging by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) offers the advantage of functional tissue characterization that is largely independent of morphologic criteria. We compared 18F-FDG PET to computed tomography (CT) in the posttreatment evaluation of 54 patients with Hodgkin's disease (HD) or intermediate/high-grade non-Hodgkin's lymphoma (NHL). Residual masses on CT were observed in 13 of 19 patients with HD and 11 of 35 patients with NHL. Five of 24 patients with residual masses on CT versus 1 of 30 patients without residual masses presented a positive 18F-FDG PET study. Relapse occurred in all 6 patients (100%) with a positive 18F-FDG PET, 5 of 19 patients (26%) with residual masses on CT but negative 18F-FDG PET, and 3 of 29 patients (10%) with negative CT scan and 18F-FDG PET studies (P </=.0001). We observed a higher relapse and death rate in patients with residual masses at CT compared with patients without residual masses at CT (progression-free survival at 1 year: 62 +/- 10 v 88 +/- 7%, P =. 0045; overall survival at 1 year: 77 +/- 5 v 95 +/- 5%, P =.0038). A positive 18F-FDG PET study was even more consistently associated with poorer survival: compared with patients with a negative 18F-FDG PET study, the 1-year progression-free survival was 0% versus 86% +/- 5% (P <.0001) and the 1-year overall survival was 50% +/- 20% versus 92% +/- 4% (P <.0001). The detection of vital tumor by 18F-FDG PET after the end of treatment has a higher predictive value for relapse than classical CT scan imaging (positive predictive value: 100% v 42%). This could help identify patients requiring intensification immediately after completion of chemotherapy. However, 18F-FDG PET mainly predicts for early progression but cannot exclude the presence of minimal residual disease, possibly leading to a later relapse.
Disciplines :
Hematology
Author, co-author :
Jerusalem, Guy  ;  Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Beguin, Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Fassotte, Marie-France ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Najjar, F.
Paulus, P.
Rigo, Pierre ;  Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et médecine nucléaire
Fillet, Georges ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Publication date :
1999
Journal title :
Blood
ISSN :
0006-4971
eISSN :
1528-0020
Publisher :
American Society of Hematology, Washington, United States - District of Columbia
Volume :
94
Issue :
2
Pages :
429-33
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 23 March 2009

Statistics


Number of views
61 (8 by ULiège)
Number of downloads
4 (0 by ULiège)

Scopus citations®
 
525
Scopus citations®
without self-citations
504
OpenCitations
 
18

Bibliography


Similar publications



Contact ORBi